Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.87M

The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company continues to expect gross margin for the full year 2026 to be approximately 75%. Pulmonx continues to expect total operating expenses for the full year 2026 to fall within the range of $113 million to $115 million, inclusive of approximately $19 million of non-cash stock-based compensation. The Company continues to expect cash, cash equivalents, and marketable securities to decrease by approximately $23 million for the full year 2026 assuming no additional drawdowns under the Company’s credit facility.”